证券代码：301363 证券简称：美好医疗 公告编号：2024-057 深圳市美好创亿医疗科技股份有限公司 关于变更部分募集资金用途的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 深圳市美好创亿医疗科技股份有限公司（以下简称"公司"或"美好医疗"） 于 2024 年 11 月 20 日分别召开第二届董事会第十五次会议、第二届监事会第十 二次会议，审议通过了《关于变更部分募集资金用途的议案》，同意公司变更部 分募集资金用途，将原计划用于"美好创亿呼吸系统疾病诊疗关键设备及呼吸健 康大数据管理云平台研发生产项目"的剩余未使用募集资金（包含利息收入、理 财收益扣除银行手续费的净额等，具体金额以实际结转时募集资金账户余额为准） 用于实施新项目"境外医疗器械生产销售平台项目"，差额部分公司将以自有资 金或自筹资金补足。保荐机构对该事项出具了无异议的核查意见。 上述事项不构成关联交易，亦不构成《上市公司重大资产重组管理办法》规 定的重大资产重组。根据《深圳证券交易所上市公司自律监管指引第 2 号——创 业板上市公司规范运作》《公司章程》和公司《募集资金管理制度》等 ...

证券代码：301363 证券简称：美好医疗 公告编号：2024-055 深圳市美好创亿医疗科技股份有限公司 第二届董事会第十五次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 深圳市美好创亿医疗科技股份有限公司（以下简称"公司"）第二届董事会 第十五次会议通知于2024年11月15日以书面、电话等方式送达全体董事，并于 2024年11月20日在公司会议室以现场结合通讯方式召开会议。本次会议由董事长 熊小川先生主持，会议应到董事7人，实际参会董事7人，其中吴学斌先生、王建 新先生、梁永晔先生、孙超先生以通讯表决方式参会。经全体与会董事确认，本 次会议的召集、召开以及审议程序符合《中华人民共和国公司法》《公司章程》 和《董事会议事规则》等有关规定，会议形成的决议合法、有效。 二、董事会会议审议情况 经全体与会董事认真审议、充分讨论，会议审议并通过了以下议案： （一）审议通过《关于变更部分募集资金用途的议案》 经审议，董事会认为：本次变更部分募集资金用途符合公司战略规划安排， 不存在损害股东利益的情形，符合《上市公司监管指引第2 ...

证券代码：301363 证券简称：美好医疗 公告编号：2024-056 深圳市美好创亿医疗科技股份有限公司 第二届监事会第十二次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 深圳市美好创亿医疗科技股份有限公司（以下简称"公司"）第二届监事会 第十二次会议通知于2024年11月15日以书面、电话等方式送达全体监事，并于 2024年11月20日在公司会议室召开现场会议。本次会议由监事会主席黎莎女士主 持，会议应到监事3人，实到监事3人，会议的召集和召开符合《中华人民共和国 公司法》《公司章程》等相关规定。 二、监事会会议审议情况 经全体与会监事认真审议、充分讨论，会议审议并通过了以下议案： （一）审议通过《关于变更部分募集资金用途的议案》 经审议，监事会认为：本次变更部分募集资金用途是结合市场环境及公司发 展实际情况而做出的合理决策，符合公司战略发展需要，有利于提高募集资金使 用效益，促进公司业务持续稳定发展，不存在损害股东利益的情形。本次变更部 分募集资金用途事项履行了必要的决策程序，符合相关法律法规和《公司章程》 的规定 ...

证券代码：301363 证券简称：美好医疗 公告编号：2024 -0 5 3 深圳市美好创亿医疗科技股份有限公司 关于回购公司股份的进展公告 | 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 | | --- | | 假记载、误导性陈述或重大遗漏。 | 深圳市美好创亿医疗科技股份有限公司（以下简称"公司"）于 2024 年 3 月 27 日召开第二届董事会第九次会议，审议通过了《关于回购公司股份方案的 议案》。同意公司使用不低于人民币 5,000 万元（含），不超过人民币 10,000 万 元（含）的自有资金以集中竞价交易方式回购公司已发行的部分人民币普通股 A 股股份，回购的股份将全部用于实施股权激励计划或员工持股计划，回购期限自 公司董事会审议通过回购方案之日起 12 个月内。具体内容详见公司分别于 2024 年 3 月 28 日、2024 年 4 月 4 日在巨潮资讯网（www.cninfo.com.cn）披露的《关 于回购公司股份方案的公告》（公告编号：2024-011）和《回购报告书》（公告 编号：2024-013）。 根据《上市公司股份回购规则》《深圳证券交易所上市公司自律监管指 ...

Investment Rating - Maintains a "Buy" rating for the company [1][3] Core Views - Q3 performance showed significant year-on-year growth, with revenue reaching 4.50 billion yuan, up 55.68% YoY and 5.94% QoQ [1] - Net profit attributable to the parent company in Q3 was 886.7 million yuan, up 49.91% YoY but down 20.21% QoQ due to exchange rate losses and share-based payments [1] - The company's diversified business layout is entering a harvest period, with the insulin pen project achieving batch delivery in Q3 [1] - Domestic and overseas production capacity continues to expand, enhancing global service capabilities [1] Financial Performance - Revenue for Q1-Q3 2024 was 11.57 billion yuan, up 10.86% YoY [1] - Net profit attributable to the parent company for Q1-Q3 2024 was 2.58 billion yuan, down 14.07% YoY [1] - Gross margin in Q3 was 42.97%, up 3.05 percentage points YoY and 0.12 percentage points QoQ [1] - Sales expense ratio in Q3 was 3.19%, up 0.31 percentage points YoY and 1.61 percentage points QoQ [1] - R&D expense ratio in Q3 was 10.21%, up 0.75 percentage points YoY and 2.05 percentage points QoQ [1] Business Development - The insulin pen project has achieved full automated production and delivery capabilities, with small batch deliveries starting in H1 2024 and batch deliveries in Q3 [1] - The company is expanding its downstream application fields, focusing on blood glucose management, in vitro diagnostics, cardiovascular, orthopedic, and MAH sectors [1] - Overseas production capacity is being enhanced, with the Malaysian factory expanding to meet global demand [1] Future Projections - Revenue for 2024-2026 is projected to be 16.14 billion yuan, 19.75 billion yuan, and 24.06 billion yuan, with YoY growth rates of 20.7%, 22.4%, and 21.8% respectively [1] - Net profit attributable to the parent company for 2024-2026 is projected to be 3.80 billion yuan, 4.65 billion yuan, and 5.75 billion yuan, with YoY growth rates of 21.3%, 22.3%, and 23.7% respectively [1] - The company's PE ratio for 2024-2026 is projected to be 33X, 27X, and 22X respectively [1] Industry Context - The company operates in the medical device industry [3] - The stock price has shown significant volatility compared to the CSI 300 index [4]

Investment Rating - The investment rating for the company is "Buy" [1]. Core Views - The report highlights that the impact of inventory destocking in downstream markets is diminishing, and several new business initiatives are contributing to growth [1]. - The company achieved a revenue of 1.157 billion yuan in Q3 2024, reflecting a year-on-year increase of 10.86%, while the net profit attributable to the parent company was 88.67 million yuan, up 56% year-on-year [1]. - The report indicates that the company's household respiratory machine business has reached a stable production and sales balance, suggesting a positive outlook for future growth [1]. Financial Performance Summary - For the first three quarters of 2024, the company reported total revenue of 1.157 billion yuan, with a net profit of 258 million yuan, representing a year-on-year decrease of 14.07% [1]. - The gross profit margin for Q3 2024 was 41.78%, showing recovery from the previous quarter's 38.29% [1]. - The report projects revenues of 1.673 billion yuan, 2.084 billion yuan, and 2.588 billion yuan for 2024, 2025, and 2026 respectively, with year-on-year growth rates of 25.0%, 24.6%, and 24.2% [2][3]. Business Development Summary - The company is expanding its new business segments, including blood glucose management and insulin injection pens, which have shown promising growth and customer acceptance [1]. - The report emphasizes that the company is actively exploring new markets and technologies, particularly in the IVD (in vitro diagnostics) sector, which could enhance its long-term growth prospects [1]. - The company is expected to benefit from production scale effects as its Malaysian factory ramps up operations, alongside the growth of new business lines [1].

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company has shown significant growth in Q3, with new business segments entering a harvest phase. The core business of home respiratory devices and cochlear implant components remains stable, with inventory pressures easing for downstream customers. The company achieved a strong performance in the first three quarters of 2024, with Q3 revenue reaching 450 million yuan, a year-on-year increase of 55.68% [1][2] - The diversified business layout initiated by the company is gradually entering a harvest period in 2024, particularly in the blood glucose management sector, where overseas B-end customer orders have been secured. The company is also focusing on high-end consumables in the in vitro diagnostics sector and making steady progress in cardiovascular technology development [1][2] Financial Performance Summary - For the first three quarters of 2024, the company reported operating revenue of 1.157 billion yuan (up 10.86% year-on-year) and a net profit attributable to the parent company of 258 million yuan (down 14.07% year-on-year). The net profit after deducting non-recurring gains and losses was 248 million yuan (down 11.15% year-on-year) [1] - The company expects revenues for 2024, 2025, and 2026 to be 1.693 billion yuan, 2.116 billion yuan, and 2.659 billion yuan, respectively, with year-on-year growth rates of 26.5%, 25.0%, and 25.7% [2][5] - The net profit attributable to the parent company is projected to be 397 million yuan, 505 million yuan, and 641 million yuan for 2024, 2025, and 2026, respectively, with corresponding growth rates of 26.6%, 27.3%, and 26.9% [2][5] Key Financial Metrics - The company’s gross margin is expected to remain stable around 41% over the forecast period, with a return on equity (ROE) projected to increase from 9.8% in 2023 to 13.6% in 2026 [2][6] - Earnings per share (EPS) are forecasted to be 0.98 yuan, 1.24 yuan, and 1.58 yuan for 2024, 2025, and 2026, respectively, with corresponding price-to-earnings (P/E) ratios decreasing from 47.79 to 22.17 over the same period [2][6]

Investment Rating - The investment rating for the company is "Outperform the Market" [6][10][13] Core Views - The company has shown impressive performance in Q3 2024, with revenue growth of 55.68% year-on-year, reaching 450 million yuan, while net profit increased by 49.91% to 89 million yuan. However, net profit was impacted by foreign exchange losses and share-based payment expenses [1][2] - The gross margin improved to 42.97%, up by 3.04 percentage points, primarily due to the clearance of inventory in the respiratory device component business [2] - The company is expanding its production capacity, with successful completion of phases one and two in Malaysia and ongoing construction of phase three, indicating confidence in meeting global supply demands [3] Summary by Sections Financial Performance - For the first three quarters of 2024, the company achieved revenue of 1.157 billion yuan, a year-on-year increase of 10.86%, while net profit attributable to shareholders was 258 million yuan, down 14.07% [1] - Q3 2024 saw a significant recovery with revenue of 450 million yuan and net profit of 89 million yuan, despite a 20% decline in net profit compared to the previous quarter due to foreign exchange losses and share-based payment expenses [1][2] Cost and Margin Analysis - The company's financial metrics showed a gross margin of 42.97%, an increase of 3.04 percentage points, while the financial expense ratio rose to 2.57%, primarily due to increased foreign exchange losses [2] - The total expense ratio increased to 23.00%, reflecting changes in sales, management, and R&D expenses [2] Capacity and Incentives - The company is enhancing its production capacity across multiple bases, with significant expansions in its Huizhou facility and the successful launch of new production phases in Malaysia [3] - A stock incentive plan was introduced, aiming for revenue and net profit growth rates of no less than 25% and 56.25% for 2024 and 2025, respectively, indicating strong confidence in future growth [3] Earnings Forecast - The company maintains its earnings forecast, projecting revenues of 1.674 billion yuan, 2.079 billion yuan, and 2.562 billion yuan for 2024, 2025, and 2026, respectively, with corresponding net profits of 392 million yuan, 487 million yuan, and 601 million yuan [3][5]

我先做完解读后续之后我没有解读到的如果投资人还有其他的问题的话我们可以在后面可以继续的交流好吗首先美好医疗三季度的这个季报确实是比较亮眼的那三季度我们是实现了营收是4.5个亿 那是再创新高那么对比2024年的第一季度第二季度第三季度来讲的话这个每个季度的营收都是在足的季度的这个在增长而且从二季度开始我们一直在不断的创这个营收的新高回顾一下过往的数据Q1的话就是第一季度的话我们美好医疗的这个营收是2.82亿那第二季度三季度的这个营收是4.25亿 那么第三季度单季度营收是4.5亿那么同时我们单季度第三季度的这个归属于上述公司股东的金利润的这个增长也是非常的强劲的也叫上上一年度同期也是增长了49.91%的所以从这个可能大家可以看到就是整个一到九月份的综合的毛利可能看到可能比去年同期略微下滑了一个点 那其实这个呢我可以把这个数据拆解给大家分析一下从这个2024年第一季度到第三季度其实公司的这个毛利是每个季度就是每个季度是逐渐增长 那么现在整个一到九月份的综合毛利上年同期下滑一个点主要还是因为我们第一季度因为大多数区域层的一个尾部的影响以及第一季度春节放假的一个影响因为第一季度的毛利大家也看到综合毛利大概是38.29 ...